A detailed history of Parallel Advisors, LLC transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 199 shares of IRWD stock, worth $817. This represents 0.0% of its overall portfolio holdings.

Number of Shares
199
Holding current value
$817
% of portfolio
0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.93 - $7.04 $782 - $1,400
199 New
199 $0
Q1 2024

May 06, 2024

SELL
$8.32 - $15.45 $2,537 - $4,712
-305 Reduced 15.87%
1,617 $14,000
Q4 2023

Feb 09, 2024

BUY
$8.79 - $11.51 $6,838 - $8,954
778 Added 68.01%
1,922 $21,000
Q3 2023

May 20, 2024

SELL
$8.25 - $11.35 $6,047 - $8,319
-733 Reduced 39.05%
1,144 $11,000
Q3 2023

Nov 13, 2023

SELL
$8.25 - $11.35 $6,047 - $8,319
-733 Reduced 39.05%
1,144 $11,000
Q2 2023

May 20, 2024

BUY
$10.1 - $11.6 $1,939 - $2,227
192 Added 11.39%
1,877 $19,000
Q2 2023

Aug 04, 2023

BUY
$10.1 - $11.6 $1,939 - $2,227
192 Added 11.39%
1,877 $19,000
Q1 2023

May 20, 2024

BUY
$10.37 - $12.56 $705 - $854
68 Added 4.21%
1,685 $17,000
Q1 2023

Apr 25, 2023

BUY
$10.37 - $12.56 $6,616 - $8,013
638 Added 60.94%
1,685 $17,000
Q4 2022

Feb 03, 2023

BUY
$9.9 - $12.43 $1,366 - $1,715
138 Added 15.18%
1,047 $12,000
Q3 2022

Nov 10, 2022

BUY
$10.14 - $12.38 $1,754 - $2,141
173 Added 23.51%
909 $9,000
Q2 2022

Aug 01, 2022

BUY
$11.05 - $12.72 $7,480 - $8,611
677 Added 1147.46%
736 $8,000
Q1 2022

Apr 28, 2022

BUY
$10.61 - $12.88 $625 - $759
59 New
59 $1,000
Q4 2021

Jan 20, 2022

SELL
$10.86 - $13.95 $238 - $306
-22 Closed
0 $0
Q3 2021

Nov 02, 2021

BUY
$11.92 - $13.92 $262 - $306
22 New
22 $0
Q3 2019

Nov 01, 2019

SELL
$8.59 - $10.96 $927 - $1,183
-108 Closed
0 $0
Q2 2019

Aug 05, 2019

BUY
$9.8 - $12.89 $1,058 - $1,392
108 New
108 $1,000

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $630M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.